(NYSE: BIO) Bio Rad Laboratories's forecast annual revenue growth rate of 1.84% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Bio Rad Laboratories's revenue in 2026 is $2,589,900,000.On average, 7 Wall Street analysts forecast BIO's revenue for 2026 to be $69,392,823,614, with the lowest BIO revenue forecast at $66,395,524,638, and the highest BIO revenue forecast at $72,711,261,766. On average, 7 Wall Street analysts forecast BIO's revenue for 2027 to be $71,212,612,278, with the lowest BIO revenue forecast at $66,395,524,638, and the highest BIO revenue forecast at $75,869,130,330.
In 2028, BIO is forecast to generate $73,246,493,726 in revenue, with the lowest revenue forecast at $67,278,657,372 and the highest revenue forecast at $79,026,998,894.